While decreases in blood glucose, insulin, plasma triglycerides, and low-density cholesterols and increases in high-density cholesterols were observed in T2DM non-human primates and humans treated with LY2405319 (9, 11), another FGF21 analog, PF-05231023, in contrast, had minimal effect on glucose and insulin in humans and monkeys (46). This evidence concerns the gene INS and type 2 diabetes mellitus.